Search Articles
Filter Articles
Found 2,734 articles
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial
- 9 Nov 2023
Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) versus TACE alone in patients with hepatocellular carcinoma (HCC) eligible for embolisation.
UK biotech fundraising picks up with best quarterly total since 2021
- 9 Nov 2023
The UK biotech sector secured a substantial total of £563 million in venture capital and public financing during the three months spanning June to August 2023, data published today by the UK BioIndustry Association (BIA) and Clarivate shows.
Dipharma SA confirms the recognition as one of the best companies to work for in Switzerland
- 8 Nov 2023
Dipharma SA, Swiss pharma for rare diseases, recognized twice as Best Place to Work. 100% employees rate it as an excellent employer, praising leadership, culture, and teamwork.
New study validates Senzime’s TetraGraph waveforms using an AI-based neural network
- 8 Nov 2023
Senzime's study validates TetraGraph with AI, achieving over 99% accuracy, published in BJA Open
Leveraging Employee Referral Programs to Locate Top Life Science Talent
- 8 Nov 2023
As a recruitment professional in the life science industry, employee referral programs (ERPs) are a highly effective way of expanding your talent pool, identifying high-quality candidates, and engaging both active and passive talent.
-
The Global Talent Lab Launches the 'Backing Invisible Geniuses' (BIG) UK Programme with a Founding Donation of XTX Markets and in Partnership with the UK Department for Science, Innovation and Technology
- 8 Nov 2023
The Global Talent Lab, in partnership with XTX Markets and the UK Department for Science, Innovation, and Technology (DSIT), proudly introduces the BIG UK Programme. This initiative is designed to identify and nurture global talent, positioning them to push the boundaries in mathematics, science, and AI.
BioMed X Launches a New Call for Application in Autoimmune Disease Research
- 8 Nov 2023
BioMed X, an independent biomedical research institute, announced yesterday the launch of a Call for Application in immunology. This call aims to assemble a new research team to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune disease.
AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer
- 8 Nov 2023
AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with 212Pb-ADVC001, a Targeted Alpha Therapy in development for the treatment of PSMA-positive metastatic CastrationResistant Prostate Cancer (mCRPC).
Rejuvenation Startup Summit 2024 announces first set of speakers
- 8 Nov 2023
Berlin's Rejuvenation Summit, May '24: CEOs, startups, investors meet for anti-aging biotech advancements. Network, invest, reverse aging diseases.
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
- 7 Nov 2023
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month progression-free survival (PFS) rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study.
Appointment of Non-Executive Directors
- 7 Nov 2023
Alliance Pharma plc (AIM: APH), the international healthcare group, is pleased to announce the appointment of Eva-Lotta Sjöstedt and Richard McKenzie as new independent Non-Executive Directors to strengthen the Board and support the delivery of the Company's growth strategy. Both Eva-Lotta and Richard will join the Board with immediate effect.
Royal Orthopaedic Hospital Welcomes Mayor of West Midlands, Andy Street
- 7 Nov 2023
Andy Street, Mayor of the West Midlands visited the Royal Orthopaedic Hospital, in Northfield, to learn more about wellbeing work at the Trust, and how colleagues are being supported as part of the West Midlands Combined Authority (WMCA) Thrive at Work programme.
How AI is Transforming Drug Discovery: Bio-IT World Europe Participants to Share Groundbreaking Advances 29-30 November in London
- 7 Nov 2023
Bio-IT World Conference & Expo to Foster Collaboration Among Life Sciences, IT and Healthcare Leaders Who are Redefining Precision Medicine
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
- 7 Nov 2023
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the open-label safety lead-in of its integrated AIPAC-003 Phase II/III trial evaluating for the very first time 90mg of eftilagimod alpha (efti) in combination with paclitaxel has been completed with no safety or tolerability issues.
Top Pharma Companies Hiring In November
- 6 Nov 2023
Here's a list of the top pharma and life science companies hiring in November on PharmiWeb.jobs
Top Pharma Recruiters in November 2023
- 6 Nov 2023
Here are the top Pharma and Life Science recruitment organisations advertising in November on PharmiWeb.jobs
Syneos Health Signs Agreement with P3 Research Ltd Network to Support Clinical Trials in New Zealand
- 6 Nov 2023
Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, has signed an agreement with P3 Research Ltd Network. The agreement further expands the Company’s clinical trial capabilities across a broader range of therapeutic areas in New Zealand (NZ).
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day
- 3 Nov 2023
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2023, and provided recent corporate updates.
Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients
- 3 Nov 2023
Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the closing of a CHF25 million Series C financing led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group, Fresenius Medical Care Ventures and Red Alpine joined in the round.
MedX Announces the Appointment of Jeffrey Morris as VP of Sales and Marketing
- 3 Nov 2023
MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce the appointment of veteran healthcare industry leader Jeffrey Morris as Vice President of Sales and Marketing.
